ID   GIST48
AC   CVCL_7041
SY   GIST-48; GIST 48
DR   cancercelllines; CVCL_7041
DR   ChEMBL-Cells; CHEMBL4513107
DR   ChEMBL-Targets; CHEMBL4513125
DR   Cosmic; 1180673
DR   Cosmic; 1873950
DR   GEO; GSM486229
DR   GEO; GSM2527252
DR   GEO; GSM2527253
DR   GEO; GSM2786737
DR   Progenetix; CVCL_7041
DR   PubChem_Cell_line; CVCL_7041
DR   Wikidata; Q54835858
RX   PubMed=16954519;
RX   PubMed=16982758;
RX   PubMed=19706776;
RX   PubMed=22294416;
RX   PubMed=22665524;
RX   PubMed=29866822;
RX   PubMed=30488756;
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Asp820Ala (c.2459A>C); ClinVar=VCV000953798; Zygosity=Heterozygous (PubMed=16954519; PubMed=16982758).
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Val560Asp (c.1679T>A); ClinVar=VCV000375914; Zygosity=Homozygous (PubMed=16954519; PubMed=16982758).
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Cell type: Interstitial cell of Cajal; CL=CL_0002088.
DI   NCIt; C3868; Gastrointestinal stromal tumor
DI   ORDO; Orphanet_44890; Gastrointestinal stromal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 18
//
RX   PubMed=16954519; DOI=10.1200/JCO.2006.06.2265;
RA   Heinrich M.C., Corless C.L., Blanke C.D., Demetri G.D., Joensuu H.,
RA   Roberts P.J., Eisenberg B.L., von Mehren M., Fletcher C.D.M., Sandau K.,
RA   McDougall K., Ou W.-B., Chen C.-J., Fletcher J.A.;
RT   "Molecular correlates of imatinib resistance in gastrointestinal
RT   stromal tumors.";
RL   J. Clin. Oncol. 24:4764-4774(2006).
//
RX   PubMed=16982758; DOI=10.1158/0008-5472.CAN-06-0165;
RA   Bauer S., Yu L.K., Demetri G.D., Fletcher J.A.;
RT   "Heat shock protein 90 inhibition in imatinib-resistant
RT   gastrointestinal stromal tumor.";
RL   Cancer Res. 66:9153-9161(2006).
//
RX   PubMed=19706776; DOI=10.1158/0008-5472.CAN-08-4004; PMCID=PMC2905726;
RA   Muhlenberg T., Zhang Y.-X., Wagner A.J., Grabellus F., Bradner J.E.,
RA   Taeger G., Lang H., Taguchi T., Schuler M., Fletcher J.A., Bauer S.;
RT   "Inhibitors of deacetylases suppress oncogenic KIT signaling,
RT   acetylate HSP90, and induce apoptosis in gastrointestinal stromal
RT   tumors.";
RL   Cancer Res. 69:6941-6950(2009).
//
RX   PubMed=22294416; DOI=10.1002/path.3986; PMCID=PMC3992120;
RA   Edris B., Espinosa I., Muhlenberg T., Mikels A., Lee C.-H.,
RA   Steigen S.E., Zhu S., Montgomery K.D., Lazar A.J.F., Lev D.C.,
RA   Fletcher J.A., Beck A.H., West R.B., Nusse R., van de Rijn M.;
RT   "ROR2 is a novel prognostic biomarker and a potential therapeutic
RT   target in leiomyosarcoma and gastrointestinal stromal tumour.";
RL   J. Pathol. 227:223-233(2012).
//
RX   PubMed=22665524; DOI=10.1158/1535-7163.MCT-12-0223; PMCID=PMC3992122;
RA   Heinrich M.C., Marino-Enriquez A., Presnell A., Donsky R.S.,
RA   Griffith D.J., McKinley A., Patterson J., Taguchi T., Liang C.-W.,
RA   Fletcher J.A.;
RT   "Sorafenib inhibits many kinase mutations associated with
RT   drug-resistant gastrointestinal stromal tumors.";
RL   Mol. Cancer Ther. 11:1770-1780(2012).
//
RX   PubMed=29866822; DOI=10.1073/pnas.1802079115; PMCID=PMC6016782;
RA   Hemming M.L., Lawlor M.A., Zeid R., Lesluyes T., Fletcher J.A.,
RA   Raut C.P., Sicinska E.T., Chibon F., Armstrong S.A., Demetri G.D.,
RA   Bradner J.E.;
RT   "Gastrointestinal stromal tumor enhancers support a transcription
RT   factor network predictive of clinical outcome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E5746-E5755(2018).
//
RX   PubMed=30488756; DOI=10.1080/15384101.2018.1553335; PMCID=PMC6300111;
RA   Tu Y.-Q., Zuo R., Ni N., Eilers G., Wu D.-L., Pei Y.-T., Nie Z.-M.,
RA   Wu Y.-Q., Wu Y.-H., Ou W.-B.;
RT   "Activated tyrosine kinases in gastrointestinal stromal tumor with
RT   loss of KIT oncoprotein expression.";
RL   Cell Cycle 17:2577-2592(2018).
//